| Literature DB >> 25719381 |
Mikhail Sokolnikov1, Dale Preston2, Ethel Gilbert3, Sara Schonfeld4, Nina Koshurnikova1.
Abstract
Radiation effects on mortality from solid cancers other than lung, liver, and bone cancer in the Mayak worker cohort: 1948-2008. The cohort of Mayak Production Association (PA) workers in Russia offers a unique opportunity to study the effects of prolonged low dose rate external gamma exposures and exposure to plutonium in a working age population. We examined radiation effects on the risk of mortality from solid cancers excluding sites of primary plutonium deposition (lung, liver, and bone surface) among 25,757 workers who were first employed in 1948-1982. During the period 1948-2008, there were 1,825 deaths from cancers other than lung, liver and bone. Using colon dose as a representative external dose, a linear dose response model described the data well. The excess relative risk per Gray for external gamma exposure was 0.16 (95% CI: 0.07 - 0.26) when unadjusted for plutonium exposure and 0.12 (95% CI 0.03 - 0.21) when adjusted for plutonium dose and monitoring status. There was no significant effect modification by sex or attained age. Plutonium exposure was not significantly associated with the group of cancers analyzed after adjusting for monitoring status. Site-specific risks were uncertainly estimated but positive for 13 of the 15 sites evaluated with a statistically significant estimate only for esophageal cancer. Comparison with estimates based on the acute exposures in atomic bomb survivors suggests that the excess relative risk per Gray for prolonged external exposure in Mayak workers may be lower than that for acute exposure but, given the uncertainties, the possibility of equal effects cannot be dismissed.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25719381 PMCID: PMC4342229 DOI: 10.1371/journal.pone.0117784
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
General description of the Mayak Worker Cohort (MWC) by gender, workplace and period of first hire.
| Workers | Exposure charachteristics | Follow-up | ||||||
|---|---|---|---|---|---|---|---|---|
| External exposure | Plutonium | Deaths | Unknown cause (%) | Lost to follow-up (%) | Lost to follow-up before 2004 (%)†† | |||
| Mean external dose | Monitored for Pu | Mean liver dose | ||||||
|
| 25,757 | 354 | 7,059 | 266 | 12,438 | 0.6% | 22.9% | 4.9% |
|
| ||||||||
| Males | 19,395 | 366 | 4,937 | 207 | 9,916 | 0.7% | 22.9% | 5.1% |
| Females | 6,362 | 317 | 2,122 | 403 | 2,522 | 0.2% | 22.9% | 4.2% |
|
| ||||||||
| Auxiliary departments | 3,384 | 76 | 55 | 16 | 1,386 | 0.9% | 26.7% | 5.9% |
| Reactor | 5,416 | 334 | 307 | 41 | 2,700 | 0.7% | 21.5% | 4.7% |
| Radiochemical | 9,194 | 601 | 3,683 | 203 | 4,586 | 0.6% | 23.5% | 5.4% |
| Plutonium Auxiliary | 3,505 | 114 | 1,130 | 162 | 1,574 | 0.4% | 23.2% | 5.5% |
| Plutonium Main 2 (High Transportability) | 1,994 | 155 | 920 | 103 | 952 | 0.2% | 16.1% | 1.8% |
| Plutonium Main 1 (Low Transportability) | 2,264 | 359 | 964 | 870 | 1,240 | 0.7% | 23.5% | 3.7% |
|
| ||||||||
| 1948–53 | 9,213 | 690 | 2,181 | 685 | 5,968 | 0.2% | 25.4% | 8.4% |
| 1954–58 | 4,221 | 349 | 1,228 | 168 | 2,207 | 0.6% | 27.9% | 5.1% |
| 1959–63 | 4,378 | 162 | 1,256 | 91 | 2,128 | 1.0% | 28.0% | 3.9% |
| 1964–72 | 3,675 | 88 | 1,209 | 35 | 1,352 | 1.8% | 16.8% | 1.5% |
| 1973–82 | 4,270 | 59 | 1,185 | 15 | 783 | 1.2% | 12.3% | 1.1% |
† 5-year lagged cumulative colon dose at end of follow-up. External dose means include those with zero external exposure. Internal dose means are based on workers with urine bioassay-based dose estimates only.
†† Percentage of total number of workers.
Definition and selected characteristics of plutonium exposure surrogate categories.
| Category | Definition | People | Monitored for Pu exposure (%) | Mean Dose | ||
|---|---|---|---|---|---|---|
| Workplace | Period of hire | External colon (mGy) | Internal liver (mGy) | |||
| 0 | Reactor complex or Auxiliary plants | 1948–1982 | 9,293 | 3.3% | 222 | 43 |
| 1 | Radiochemical or any Plutonium | 1964–1982 | 4,891 | 49.4% | 77 | 26 |
| 2 | Radiochemical or Plutonium auxiliary | 1954–1963 | 5,931 | 39.9% | 324 | 105 |
| or Plutonium Main 2 | 1959–1963 | |||||
| 3 | Radiochemical or Plutonium auxiliary | 1948–1953 | 5,329 | 35.5% | 810 | 419 |
| or Plutonium Main 2 | 1950–1958 | |||||
| or Plutonium Main 1 | 1959–1963 | |||||
| 4 | Plutonium Main 2 | 1948–1949 | 740 | 36.4% | 319 | 476 |
| or Plutonium Main 1 | 1954–1958 | |||||
| 5 | Plutonium Main 1 | 1948–1953 | 573 | 37.0% | 914 | 3,170 |
|
|
|
|
|
| ||
† 5-year lagged cumulative dose at end of follow-up. Internal dose means based on workers with urine bioassay-based dose estimates.
Number of workers and mean doses by sex, period of hire and primary plant.
| Period of Hire | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1948–53 | 1954–58 | 1959–63 | 1964–72 | 1973–82 | |||||||||||
| People | Ext. dose | Int. dose | People | Ext. dose | Int. dose | People | Ext. dose | Int. dose | People | Ext. dose | Int. dose | People | Ext. dose | Int. dose | |
|
| |||||||||||||||
|
| 523 | 171 | 115 | 310 | 97 | 32 | 440 | 56 | 4 | 717 | 55 | 15 | 719 | 36 | 5 |
|
| 184 | 146 | — | 47 | 50 | — | 114 | 70 | 7 | 183 | 37 | 1 | 147 | 27 | 4 |
|
| |||||||||||||||
|
| 1,768 | 621 | 47 | 575 | 360 | 34 | 643 | 239 | 40 | 481 | 179 | 70 | 771 | 99 | 6 |
|
| 676 | 226 | 83 | 151 | 105 | 28 | 70 | 70 | 24 | 78 | 69 | 14 | 203 | 50 | 9 |
|
| |||||||||||||||
|
| 2,333 | 1,196 | 532 | 1,682 | 519 | 126 | 1,229 | 278 | 88 | 683 | 152 | 35 | 916 | 82 | 25 |
|
| 1,327 | 867 | 332 | 272 | 442 | 94 | 233 | 144 | 39 | 187 | 104 | 31 | 332 | 62 | 12 |
|
| |||||||||||||||
|
| 666 | 279 | 253 | 209 | 150 | 62 | 431 | 47 | 75 | 468 | 34 | 33 | 454 | 21 | 7 |
|
| 531 | 214 | 713 | 100 | 84 | 227 | 202 | 23 | 128 | 184 | 12 | 27 | 260 | 22 | 11 |
|
| |||||||||||||||
|
| 353 | 379 | 288 | 287 | 133 | 141 | 414 | 97 | 82 | 274 | 90 | 25 | 262 | 54 | 10 |
|
| 112 | 315 | 286 | 45 | 152 | 234 | 71 | 62 | 41 | 93 | 63 | 31 | 83 | 63 | 8 |
|
| |||||||||||||||
|
| 453 | 792 | 1,477 | 457 | 270 | 376 | 492 | 141 | 165 | 297 | 50 | 55 | 88 | 46 | 15 |
|
| 287 | 766 | 3,736 | 86 | 202 | 368 | 39 | 106 | 95 | 30 | 22 | 47 | 35 | 21 | 15 |
† Mean 5-year lagged cumulative colon dose at end of follow-up, mGy
‡ Mean 5-year lagged cumulative internal liver dose in mGy at end of follow-up for workers with urine bioassay-based internal dose estimates
— No workers monitored for plutonium exposure.
Fig 1Non-smoker baseline cancer mortality rates and their sex ratio.
Non-smoker baseline rates for mortality from solid cancers in organs other than lung, liver, bone or connective tissue in the Mayak worker cohort (upper panel) with age-specific sex ratios (lower panel).
Observed and fitted solid cancer deaths excluding lung, liver, bone, and connective tissue cancer deaths by external dose category with and without adjustment for internal exposure.
| External colon dose (Gy) | Person year | Deaths | Internal-exposure adjusted | Unadjusted | |||
|---|---|---|---|---|---|---|---|
| Background | Exposure-associated | Background | External dose associated | ||||
| External | Internal | ||||||
| <0.01 | 277,422 | 246 | 219.6 | 0.04 | 0.2 | 222.6 | 0.1 |
| -0.05 | 140,927 | 168 | 200.9 | 0.7 | 0.2 | 200.6 | 0.9 |
| -0.10 | 98,648 | 213 | 174.6 | 1.5 | 0.5 | 172.9 | 2.0 |
| -0.2 | 106,818 | 216 | 226.9 | 3.8 | 0.7 | 225.5 | 5.2 |
| -0.5 | 141,808 | 342 | 348.4 | 13.1 | 1.9 | 344.3 | 17.7 |
| -1 | 93,270 | 282 | 252.2 | 20.7 | 2.2 | 250.2 | 28.0 |
| -2 | 72,944 | 271 | 228.4 | 37.4 | 4.3 | 220.1 | 48.9 |
| -3 | 15,146 | 63 | 50.7 | 13.8 | 1.8 | 47.4 | 17.5 |
| 3+ | 3,913 | 24 | 13.7 | 5.8 | 1.0 | 13.3 | 7.7 |
|
|
|
|
|
|
|
|
|
† The baseline risk model includes an adjustment for the time-dependent Pu monitoring status and the excess relative risk includes internal dose and surrogate category effects for monitored and unmonitored workers, respectively.
‡ The baseline risk model does not include a Pu monitoring effect and there are no internal dose or surrogate effects in the ERR.
Fig 2External exposure dose response for solid cancers other than lung liver and bone.
A) External exposure dose response function for solid cancers at sites of than lung, live, bone, or connective tissue. B) The same plot for doses below 1.5 Gy. The solid line is the fitted linear dose response, the points are ERR estimates in dose categories. The thick dashed line is a non-parametric smooth fit to the categorical estimates while the thin dashed lines indicate plus or minus one standard error from the smoothed curve. The models used in this analysis included no adjustment for plutonium exposure.
External dose effect estimates from selected excess relative risk (ERR) models for solid cancers other than lung, liver, and bone cancers.
| Model/Parameter description | Estimate (95% CI | |
|---|---|---|
|
| ||
|
| ||
| Adjusted for internal exposure (ERR/Gy) | 0.12 | (0.03 to 0.21) |
| No internal exposure adjustment (ERR/Gy) | 0.16 | (0.07 to 0.26) |
|
| ||
| Linear (ERR/Gy) | 0.10 | (-0.09 to 0.30) |
| Quadratic (per Gy2) | 0.03 | (-0.05 to 0.11) |
|
| ||
| Linear (ERR/Gy) | 0.11 | (-0.05 to 0.30) |
| Cell-Killing | 0.02 | (-0.05 to 0.08) |
|
| ||
|
|
| |
|
| 0.44 | (<0 to 1.5) |
|
| -0.08 | (<-0.2 to 0.56) |
|
| 0.15 | (<0 to 0.62) |
|
| 0.16 | (0.07 to 0.27) |
|
| ||
|
|
| |
| < 25 | 0.14 | (-0.005 to 0.30) |
| 25–29 | 0.28 | (0.08 to 0.51) |
| 30–39 | 0.06 | (0.004 to 0.25) |
| 40–49 | 0.15 | (-0.09 to 0.47) |
| 50+ | 0.06 | (<-0.1 to 1.1) |
* 95% confidence interval
† Estimates made without adjustment for internal exposure. P-values are for likelihood ratio tests comparing model shown to linear time constant ERR model in lagged 5 cumulative dose. Phet refers to the P-value for a test for heterogeneity of risk estimates over categories of a variable of interest.
Cancer cases by sex and site.
| Type of cancer | Men | Women | Total |
|---|---|---|---|
|
| |||
| Stomach | 374 | 78 | 452 |
| Colon | 110 | 46 | 156 |
| Rectum | 103 | 43 | 146 |
| Pancreas | 103 | 25 | 128 |
| Breast | 107 | 107 | |
| Prostate | 80 | 80 | |
| Kidney | 61 | 17 | 78 |
| Melanoma | 23 | 15 | 38 |
| Larynx | 66 | 2 | 68 |
| Esophagus | 58 | 8 | 66 |
| Brain & central nervous system | 58 | 8 | 66 |
| Bladder | 62 | 1 | 63 |
| Ovary | 43 | 43 | |
| Uterus | 36 | 36 | |
| Other solid cancer | 236 | 65 | 301 |
| |
|
|
|
|
| |||
| Lung | 760 | 81 | 841 |
| Liver | 61 | 30 | 91 |
| Bone and soft tissue | 28 | 14 | 42 |
| |
|
|
|
|
| |||
| Leukemia | 82 | 28 | 110 |
| Other lympho-hematopoietic | 53 | 18 | 71 |
| Lympho-hematopoietic total | 135 | 46 | 181 |
|
|
|
|
|
Site-specific excess relative risk per Gy estimates‡ and number of external exposure associated cases.
| Site | Deaths | Dose | Linear risk estimate | Radiation-associated cases | ||
|---|---|---|---|---|---|---|
| ERR | 95% CI | P | ||||
| Colon | 156 | Colon | 0.21 | -0.06–0.62 | 0.13 | 14.1 |
| Esophagus | 66 | Esophagus | 1.26 | 0.36–3.27 | < 0.001 | 24.7 |
| Stomach | 452 | Stomach | 0.12 | -0.03–0.31 | 0.06 | 25.8 |
| Rectum | 146 | Rectum | 0.18 | -0.09–0.63 | 0.18 | 11.7 |
| Pancreas | 128 | Pancreas | 0.18 | -0.09–0.64 | 0.18 | 11.6 |
| Bladder | 62 | Bladder | -0.02 | <-0–0.45 | >0.5 | -0.8 |
| Kidney | 78 | Kidney | 0.08 | <-0.1–0.69 | > 0.5 | 2.8 |
| Melanoma | 38 | Hp(10) | -0.00 | <-0.1–0.77 | > 0.5 | 0.0 |
| Brain | 66 | Brain | < 0 | < -0.1 0.32 | 0.50 | -3.2 |
| Larynx | 66 | Larynx | 0.12 | <0–0.68 | >0.5 | 4.7 |
| Prostate | 80 | Prostate | 0.11 | <0–0.63 | >0.5 | 5.0 |
| Breast | 107 | Breast | 0.16 | -0.09–0.57 | >0.5 | 7.3 |
| Ovary | 43 | Ovary | 0.19 | <0–1.23 | > 0.5 | 2.7 |
| Uterus | 36 | Uterus | 0.42 | <0–1.66 | 0.23 | 4.4 |
| Remainder | 301 | Colon | 0.09 | -0.05–0.30 | 0.24 | 16.7 |
| Total excluding lung, liver bone | 1825 | Site-specific organ doses | 127.5 | |||
| Colon | 0.16 | 0.07–0.26 | < 0.001 | 127.2 | ||
| Film badge | 0.08 | 0.03–0.14 | <0.01 | 98.2 | ||
‡ The risk estimates in this table were not adjusted for plutonium exposure since, as noted in the text, there is no evidence of significant effects of plutonium for all of these cancers as a group or for any specific type of cancer considered here.
* Analyses were limited to cases seen in men with cases among women (1 bladder cancer and 2 laryngeal cancers) included in the remainder.
Excess relative risk (ERR) estimates from the A-bomb survivors and from selected studies of persons exposed to protracted low-LET external ionizing radiation.
| Study population | Mean dose | Outcome | Deaths | ERR Per Gy(Sv) | ||
|---|---|---|---|---|---|---|
|
|
| |||||
| Mayak nuclear workers | 354 | Solid cancers except lung, liver, and bone | Men: | 1,334 | 0.15 | (0.06–0.27) |
| Women: | 491 | 0.17 | (0.02–0.35) | |||
| Total: | 1,825 | 0.16 | (0.08–0.24) | |||
| A-bomb survivors exposed between 20 and 60 [ | 109 | Solid cancers except lung, liver, and bone | Men: | 2,278 | 0.30 | (0.10–0.54) |
| Women: | 3,088 | 0.52 | (0.32–0.74) | |||
| Total: | 5,366 | 0.35 | (0.19–0.55) | |||
| Nuclear workers in 15 countries [ | 19 | All except leukemia, lung, and pleura | 3,390 | 0.44 | (-0.30–1.4) | |
| United Kingdom National Registry for Radiation Workers (NRRW) [ | 25 | All except leukemia, lung, and pleura | 5,118 | 0.32 | (0.02–0.67) | |
| Techa River Cohort [ | 35 | All except leukemia | 2,303 | 0.61 | (0.13–1.2) | |
* Doses are external colon dose in mGy for Mayak workers, weighted colon dose in mGy for the atomic bomb survivors, Hp(10) in mSv for the 15-country and NRRW studies.(Hp(10) is the equivalent dose at a tissue depth of 10 mm beneath a dosimeter); stomach dose in mGy for the Techa river cohort
† 90% confidence intervals used for comparison with published results in the 15-country and NRRW studies
†† weighted average with weights of 0.75 for men and 0.25 for women to reflect the sex ratio in the Mayak worker cohort
‡ These populations are predominantly male
§ The estimate presented here is based on the 15-country study results withwith the Canadian data excluded ([29], page 405).). This estimate was used because of concerns about the Canadian data usedused in that study. This concerns have beenbeen supported by the recently published re-analysis of the Canadian workerworker data given in [34]. The ERR/SvSv estimate for using all of the 15-country data is 0.59 (95% CI <0 to 1.5, [29], page 403).
** There was no evidence that risk differed by sex in this cohort.